LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

0.76 7.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.71

Max

0.79

Põhinäitajad

By Trading Economics

Sissetulek

8.5M

-25M

Müük

-25M

1.3M

Aktsiakasum

-0.07

Kasumimarginaal

-2,004.358

Töötajad

103

EBITDA

4.1M

-26M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+409.72% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-19M

226M

Eelmine avamishind

-6.28

Eelmine sulgemishind

0.76

Uudiste sentiment

By Acuity

50%

50%

166 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. nov 2024, 12:42 UTC

Suurimad hinnamuutused turgudel

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

409.72% tõus

12 kuu keskmine prognoos

Keskmine 3.67 USD  409.72%

Kõrge 6 USD

Madal 1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

166 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.